Search

Adrian M Piliponsky

from Seattle, WA
Age ~53
Get Report
Also known as:
Adrian M Pi, Adrian M Steinman
Phone and address:
6420 57Th Ave NE, Seattle, WA 98115
Related to:
Ethan B Steinman, 48James H Daugherty, 58
Connected to:
Emina Pilipovic, 60Joshua L Pilisuk, 39Allison C Pilitsis, 74Georgena H Pilitsis, 112Jerel Pilitzer, 73Taryn Pilius, 36Milan Piljevic, 56Frank W Pilk, 73John A Pilk, 76Darlene M Pilka, 63

Adrian Piliponsky Phones & Addresses

  • 6420 57Th Ave NE, Seattle, WA 98115
  • San Francisco, CA
  • Mountain View, CA
  • Palo Alto, CA

Work

Company: Seattle children's research institute Jan 2011 Address: 1900 9th Avenue, Seattle, WA Position: Assistant professor of pediatrics

Education

Degree: Ph.D. School / High School: The Hebrew University Specialities: Cell Biology

Skills

Cell Culture • Lifesciences • Molecular Biology • Mouse Models

Industries

Research

Resumes

Resumes

Adrian Piliponsky Photo 1

Associate Professor Of Pediatrics

View page
Location:
Seattle, WA
Industry:
Research
Work:
Seattle Children's Research Institute - 1900 9th Avenue, Seattle, WA since Jan 2011
Assistant Professor of Pediatrics
Stanford University - 269 Campus Drive, CCSR 3260 Apr 2004 - Nov 2010
Post Doc and Instructor
Education:
The Hebrew University
Ph.D., Cell Biology University of Buenos Aires
BSc. Pharm, Pharmacy
Skills:
Cell Culture
Lifesciences
Molecular Biology
Mouse Models

Business Records

Name / Title
Company / Classification
Phones & Addresses
Adrian M. Piliponsky
Phd
Cf Therapeutics Development Network
Communication Network for Medical Research
1100 Olive Way, Seattle, WA 98101
(206) 987-7800

Publications

Us Patents

Neurotensin As A Marker And Therapeutic Target For Sepsis

View page
US Patent:
20080213270, Sep 4, 2008
Filed:
Oct 19, 2007
Appl. No.:
11/875710
Inventors:
Adrian Martin Piliponsky - Mountain View CA, US
Mindy Tsai - Palo Alto CA, US
Stephen J. Galli - Stanford CA, US
International Classification:
A61K 39/395
G01N 33/53
G01N 33/00
C12Q 1/02
A01K 67/027
US Classification:
4241391, 435 71, 436 86, 435 29, 800 9
Abstract:
Sepsis is a complex, incompletely understood and often fatal disorder, typically accompanied by hypotension, that is considered to represent a dysregulated host response to an infection. Neurotensin (NT) is 13-amino-acid peptide that, among its multiple effects, induces hypotension. It is shown herein that plasma concentrations of NT are increased in humans with sepsis and in mice after caecal ligation and puncture (CLP), a model of sepsis. Mast cells can degrade NT through neurotensin receptor 1- and neurolysin-dependent mechanisms, diminishing the hypotensive effects of NT, reducing intraperitoneal NT concentrations, and improving survival. These findings show that mast cells can regulate NT concentrations, and identify NT as a biomarker and therapeutic target in sepsis.

Compositions And Methods For Detecting Sepsis

View page
US Patent:
20220283153, Sep 8, 2022
Filed:
Aug 4, 2020
Appl. No.:
17/632495
Inventors:
- Seattle WA, US
Dayle L. Sampson - Seattle WA, US
Silvia Cermelli - Seattle WA, US
Therese Seldon - Seattle WA, US
Krupa Navalkar - Seattle WA, US
Adrian Piliponsky - Seattle WA, US
Assignee:
Seattle Children's Hospital d/b/a Seattle Children's Research Institute - Seattle WA
International Classification:
G01N 33/543
G01N 33/68
Abstract:
The disclosure provides a panel of biomarkers that individually or in combination can indicate the presence of sepsis as distinguishable from other non-infection related inflammatory conditions. The disclosed biomarkers and related reagents and kits provide strategies for detecting, treating, and monitoring sepsis in subjects. In aspect, the disclosure provides a method for detecting sepsis, comprising contacting a biological sample obtained from the subject with an affinity reagent that specifically binds to one or more of the disclosed novel biomarkers, and detecting differential expression of the one or more biomarkers by detecting binding of the affinity reagent to the biomarker. The method can incorporate use of additional known biomarkers. The method can further comprise treating a subject determined to have sepsis. In some embodiments, the subject is a human subject less than 20 years old.
Control profile
Adrian M Piliponsky from Seattle, WA, age ~53 Get Report